Eli Lilly's novel obesity drug has demonstrated superior weight-loss results compared to its predecessor, Zepbound, in a late-stage trial, cementing the company's dominance in an expanding market. The escalating demand for GLP-1-based drugs has pharmaceutical firms rapidly investing in advanced treatments that promise greater efficacy.

The weight-loss pharmaceutical market is on the verge of explosive growth, with projections indicating potential annual revenues of $150 billion by the next decade. As competition intensifies, companies like Novo Nordisk and Eli Lilly are at the forefront, striving to maintain their market share.

A California jury has held Johnson & Johnson accountable, ordering the company to pay $40 million to two women who attributed their ovarian cancer to the company'

See Full Page